Figure 3
From: Effects of Erythropoietin in Murine-Induced Pluripotent Cell-Derived Panneural Progenitor Cells
iPS pNPC proliferation and cell cycle analysis. The PI3K inhibitor LY294002 (A) or the MAPK-inhibitor U-0126 (B) have no consistent effect on EPO-induced reduction of pNPC proliferation (percentage of CFSElow cells after 48 h). (C) Cell cycle analysis of pNPC proliferation. EPO treatment did not change the percentage of cells in G1, S or G2-phase after 10 h of treatment in either clonal lines. Data in all panels represent mean ± SD, n = 3 (C1), n = 4 (C2); *p < 0.05, **p < 0.01 (paired t test for normal and Wilcoxon test for not normal distributed samples).